However, SGLT2i were more effective in reducing hospitalization for heart failure and progression to end-stage renal disease, whereas GLP-1 RAs showed slightly stronger effects on reducing stroke and non-fatal cardiovascular events [112,113]. Here, GLP1R is linked to chronic kidney disease.